CA2311129A1 - Utilisation de composes de diphenyle indanone, indane et indole substitues dans le traitement ou la prevention de la drepanocytose, des maladies inflammatoires caracterisees par une proliferation cellulaire anormale et par la diarrhee chez l'homme et l'animal - Google Patents

Utilisation de composes de diphenyle indanone, indane et indole substitues dans le traitement ou la prevention de la drepanocytose, des maladies inflammatoires caracterisees par une proliferation cellulaire anormale et par la diarrhee chez l'homme et l'animal Download PDF

Info

Publication number
CA2311129A1
CA2311129A1 CA002311129A CA2311129A CA2311129A1 CA 2311129 A1 CA2311129 A1 CA 2311129A1 CA 002311129 A CA002311129 A CA 002311129A CA 2311129 A CA2311129 A CA 2311129A CA 2311129 A1 CA2311129 A1 CA 2311129A1
Authority
CA
Canada
Prior art keywords
group
substituted
independently selected
absent
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002311129A
Other languages
English (en)
Inventor
Falguni M. Kher
Mark Froimowitz
Eugene W. Kelleher
Reem M. Haidar
Emile M. Bellot, Jr.
Adel M. Moussa
Jose Halperin
Seth Alper
Carlo Brugnara
Wayne I. Lencer
Ying-Duo Gao
Yesh P. Sachdeva
Richard John Lombardy
Heather N. Taft
Minghua Sun
John J. Clifford
Rudolf Fluckiger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Harvard College
Childrens Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/159,331 external-priority patent/US20020004519A1/en
Application filed by Harvard College, Childrens Medical Center Corp filed Critical Harvard College
Publication of CA2311129A1 publication Critical patent/CA2311129A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La présente invention porte sur des composés 3,3-diphényle indanone, indane et indole substitués, et sur leurs analogues, qui sont des inhibiteurs spécifiques, puissants et sûrs des vannes à potassium activées par Ca?2+¿ (canal Gardos) des hématies, de la prolifération cellulaire mammalienne et/ou de la sécrétion de chlorure électrogénique transépithélial stimulée par le sécrétagogue dans les cellules intestinales. Ces composés peuvent être utilisés pour réduire la déshydratation drépanocytaire et/ou retarder l'apparition de la falciformation ou déformation des hématies in situ dans des méthodes thérapeutiques utilisées dans le traitement ou la prévention de la drépanocytose. Ces composés peuvent être également utilisés pour inhiber la prolifération des cellules mammaliennes in situ dans des méthodes thérapeutiques utilisées dans le traitement ou la prévention de maladies caractérisées par une prolifération cellulaire anormale, ainsi que pour inhiber la sécrétion de chlorure dans les cellules intestinales dans des méthodes thérapeutiques utilisées dans le traitement de la diarrhée chez l'homme et l'animal.
CA002311129A 1997-11-20 1998-11-20 Utilisation de composes de diphenyle indanone, indane et indole substitues dans le traitement ou la prevention de la drepanocytose, des maladies inflammatoires caracterisees par une proliferation cellulaire anormale et par la diarrhee chez l'homme et l'animal Abandoned CA2311129A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US97559597A 1997-11-20 1997-11-20
US08/975,595 1997-11-20
US15933698A 1998-09-23 1998-09-23
US09/159,336 1998-09-23
US09/159,331 US20020004519A1 (en) 1998-09-23 1998-09-23 Method for reducing chloride secetion by intestinal epithlial cells in situ
US09/159,331 1998-09-23
PCT/US1998/024968 WO1999026624A1 (fr) 1997-11-20 1998-11-20 Utilisation de composes de diphenyle indanone, indane et indole substitues dans le traitement ou la prevention de la drepanocytose, des maladies inflammatoires caracterisees par une proliferation cellulaire anormale et par la diarrhee chez l'homme et l'animal

Publications (1)

Publication Number Publication Date
CA2311129A1 true CA2311129A1 (fr) 1999-06-03

Family

ID=27388300

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002311129A Abandoned CA2311129A1 (fr) 1997-11-20 1998-11-20 Utilisation de composes de diphenyle indanone, indane et indole substitues dans le traitement ou la prevention de la drepanocytose, des maladies inflammatoires caracterisees par une proliferation cellulaire anormale et par la diarrhee chez l'homme et l'animal

Country Status (6)

Country Link
EP (1) EP1032385A1 (fr)
JP (1) JP2001523717A (fr)
AU (1) AU1598899A (fr)
CA (1) CA2311129A1 (fr)
IL (1) IL136208A0 (fr)
WO (1) WO1999026624A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800658B2 (en) 1997-11-20 2004-10-05 Children's Medical Center Corporation Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment of prevention of diseases characterized by abnormal cell proliferation
US6291449B1 (en) 1998-09-23 2001-09-18 Children's Medical Center Corporation Use of 11-phenyl-dibenzazepine compounds to treat diarrhea or scours
NL1034882C2 (nl) 2008-01-02 2009-07-06 Gear Chain Ind Bv Inrichting voor het rekken van een transmissieketting.
WO2013014659A1 (fr) * 2011-07-22 2013-01-31 Venantius Limited Dérivés d'indène pouvant être utilisés dans le traitement des maladies inflammatoires de l'intestin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273992A (en) * 1992-11-02 1993-12-28 Beth Israel Hospital Assoc. Inc. Method for reducing sickle erythrocyte dehydration and delaying the occurrence of erythrocyte sickling in-situ
DE69534632T2 (de) * 1994-09-16 2006-06-14 Childrens Medical Center Clotrimazol-Metaboliten bei der Behandlung von Sichelzellenkrankheit
AU6966696A (en) * 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
JP4376970B2 (ja) * 1996-03-20 2009-12-02 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 鎌状赤血球症のためのトリアリールメタン化合物

Also Published As

Publication number Publication date
JP2001523717A (ja) 2001-11-27
IL136208A0 (en) 2001-05-20
WO1999026624A1 (fr) 1999-06-03
AU1598899A (en) 1999-06-15
EP1032385A1 (fr) 2000-09-06

Similar Documents

Publication Publication Date Title
US6331564B1 (en) Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease
US6028103A (en) Triaryl methane compounds and analogues thereof useful for the treatment or prevention of sickle cell disease or diseases characterized by abnormal cell proliferation
JP2008201783A (ja) 鎌状赤血球症のためのトリアリールメタン化合物
CA2311129A1 (fr) Utilisation de composes de diphenyle indanone, indane et indole substitues dans le traitement ou la prevention de la drepanocytose, des maladies inflammatoires caracterisees par une proliferation cellulaire anormale et par la diarrhee chez l&#39;homme et l&#39;animal
CA2310773A1 (fr) Utilisation de composes 11-phenyl-dibenzazepine substitues dans le traitement ou la prevention de la drepanocytose, des maladies inflammatoires caracterisees par une proliferationcellulaire anormale et par la diarrhee chez l&#39;homme et l&#39;animal
US6800658B2 (en) Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment of prevention of diseases characterized by abnormal cell proliferation
US20020128256A1 (en) Methods for the treatment or prevention of inflammatory diseases characterized by abnormal cell proliferation
EP1047676B1 (fr) Composes de 11-phenyl-dibenzazepine substitues, utiles dans le traitement ou la prevention des maladies se caracterisant par une proliferation de cellules etrangeres
JP4009062B2 (ja) 異常な細胞増殖を特徴とする疾患を治療または予防するために有用な、置換ジフェニルインダノン、インダン、およびインドール化合物およびそれらの類縁体
US20030134842A1 (en) Methods for the treatment or prevention of inflammatory diseases characterized by abnormal cell proliferation
US6992079B2 (en) Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
AU2640201A (en) Triaryl and diaryl compounds, their analogues and uses thereof

Legal Events

Date Code Title Description
FZDE Discontinued